drugset / Trial / NCT04471038
Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants
RandomizedSequentialQuadruple-blindTreatment
Summary
Influenza causes substantial morbidity and mortality worldwide despite available antivirals and vaccines. SAB Biotherapeutics, Inc. has developed SAB-176, an anti-influenza human immunoglobulin (transchromosomic \[Tc\] bovine-derived) intravenous therapeutic to treat past and current strains of Type A Influenza and Type B Influenza. This study will evaluate the safety, tolerability, and pharmacokinetics of SAB-176 in healthy participants.
Timeline
- Start
- 2020-07-29
- Primary completion
- 2021-04-19
- Completion
- 2021-04-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SAB-176 | Protein / enzyme biologic | 1 mg/ml | Intravenous |
| Subject | SAB-176 | Protein / enzyme biologic | 10 mg/kg | Intravenous |
| Subject | SAB-176 | Protein / enzyme biologic | 25 mg/kg | Intravenous |
| Subject | SAB-176 | Protein / enzyme biologic | 50 mg/kg | Intravenous |